Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 3 | 2 | 5 |
| 2006 | 5 | 2 | 7 |
| 2007 | 9 | 4 | 13 |
| 2008 | 15 | 5 | 20 |
| 2009 | 5 | 5 | 10 |
| 2010 | 4 | 7 | 11 |
| 2011 | 11 | 4 | 15 |
| 2012 | 10 | 4 | 14 |
| 2013 | 10 | 2 | 12 |
| 2014 | 8 | 3 | 11 |
| 2015 | 6 | 3 | 9 |
| 2016 | 5 | 3 | 8 |
| 2017 | 3 | 2 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 2 | 5 |
| 2020 | 3 | 3 | 6 |
| 2021 | 4 | 0 | 4 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Li JW, Wang JY, Yu RQ, Huo L, Zheng LW. Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid. BMC Res Notes. 2022 Jan 10; 15(1):12.
-
Hu MI. Hypercalcemia of Malignancy. Endocrinol Metab Clin North Am. 2021 12; 50(4):721-728.
-
Rachner TD, Coleman R, Hadji P, Hofbauer LC. Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. J Bone Miner Res. 2021 10; 36(10):1906-1913.
-
Reddy K, Ramirez L, Kukreja K, Venkatramani R. Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis. J Pediatr Hematol Oncol. 2021 03 01; 43(2):e215-e218.
-
Jara MA, Varghese J, Hu MI. Adverse events associated with bone-directed therapies in patients with cancer. Bone. 2022 May; 158:115901.
-
Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, Confavreux CB, Holen I. Bone metastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021 07 01; 101(3):797-855.
-
Van Poznak C, Reynolds EL, Estilo CL, Hu M, Schneider BP, Hertz DL, Gersch C, Thibert J, Thomas D, Banerjee M, Rae JM, Hayes DF. Osteonecrosis of the jaw risk factors in bisphosphonate-treated patients with metastatic cancer. Oral Dis. 2022 Jan; 28(1):193-201.
-
Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Cabanillas ME, Naing A, Myers JN, Li Y, Chambers MS. Prevalence of medication related osteonecrosis of the jaw in patients treated with sequential antiresorptive drugs: systematic review and meta-analysis. Support Care Cancer. 2021 May; 29(5):2305-2317.
-
Choe M, Smith V, Okcu MF, Wulff J, Gruner S, Huisman TAGM, Venkatramani R. Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer. 2021 03; 68(3):e28778.
-
Suarez-Almazor ME, Herrera R, Lei X, Chavez-MacGregor M, Zhao H, Giordano SH. Survival in older women with early stage breast cancer receiving low-dose bisphosphonates or denosumab. Cancer. 2020 09 01; 126(17):3929-3938.